Intensive care units serve to provide temporary physiologic support to patients with reversible organ failure. However, with increasing frequency, patients with end-stage and terminal illnesses are being admitted to the intensive care unit. Indeed, in the United States, a third of all patients with terminal metastatic malignancy are admitted to the intensive care unit, and 60% of all hospital deaths occur after such an admission. In many instances, admission to an intensive care unit serves only to transform death into a prolonged, painful, and undignified process. In patients with a terminal illness, the focus should be on measures that ensure comfort, and admission to an intensive care unit should generally be avoided. Intensivists, who are charged with making the best use of limited resources, should ultimately be the individuals who determine the appropriateness of admitting such patients to the intensive care unit.
Bone RC, McElwee NE, Eubanks DH, Gluck EH. Analysis of indications for intensive care unit admission. Clinical efficacy assessment project: American College of Physicians. Chest. 1993;104:1806-1811.
2.
Angus DC, Barnato AE, Linde-Zwirble W, et al. Use of intensive care at the end of life in the United States: an epidemiologic study. Crit Care Med. 2004;32:638-643.
3.
Rady MY, Johnson DJ. Admission to intensive care unit at the end-of-life: is it an informed decision?Palliat Med. 2004;18:705-711.
4.
Soares M, Carvalho MS, Salluh JI, et al. Effect of age on survival of critically ill patients with cancer. Crit Care Med. 2006;34:715-721.
5.
Soares M, Salluh JI, Spector N, et al. Characteristics and outcomes of cancer patients requiring mechanical ventilatory support for >24 hrs. Crit Care Med. 2005;33:520-526.
6.
Darmon M, Thiery G, Ciroldi M, et al. Intensive care in patients with newly diagnosed malignancies and a need for cancer chemotherapy. Crit Care Med. 2005;33: 2488-2493.
7.
Tanvetyanon T. Consideration before administering cytotoxic chemotherapy to the critically ill. Crit Care Med. 2005;33:2689-2691.
8.
Chadwick J, Mann WN. The Medical Works of Hippocrates. Boston, Mass: Blackwell Scientific Publications; 1950.
9.
American Nurses Association Task Force on the Nurse's role in End of Life Decisions. Position Statement on Foregoing Artificial Nutrition and Hydration. Washington, DC, American Nurses Association; 1992.
10.
American College of Physicians Ethics Manual. 3rd ed.Ann Intern Med. 1992;117:947-960.
11.
Council on Ethical and Judicial Affairs, American Medical Association. Medical futility in end-of-life care: report of the Council on Ethical and Judicial Affairs. JAMA. 1999;281:937-941.
12.
American College of Chest Physicians/Society of Critical Care Medicine Consensus Panel. Ethical and moral guidelines for the initiation, continuation, and withdrawal of intensive care. Chest. 1990;97:946-958.
13.
Current Opinions of the Council on Ethical and Judicial Affairs of the American Medical Association. Withholding or Withdrawing Life Prolonging Treatment. Chicago, Ill: American Medical Association; 1992.
14.
The SUPPORT Principal Investigators. A controlled trial to improve care for seriously ill hospitalized patients: the study to understand prognoses and preferences for outcomes and risk treatments (SUPPORT). JAMA. 1995;274:1591-1598.
15.
Garrouste-Orgeaus M, Montuclard L, Timsit JF, et al. Predictors of intensive care unit refusal in French intensive care units: a multiple-center study. Crit Care Med. 2005;33:750-755.
16.
D'Alecy LG, Kluger MJ. Avian febrile response. J Physiol1975;253:223-232.
17.
Marik PE, Kraus P, Lipman J. Intensive care utilisation: the Baragwanath experience. Anaesth Intensive Care. 1993;21:396-399.
18.
Azoulay E, Thiery G, Chevret S, et al. The prognosis of acute respiratory failure in critically ill cancer patients. Medicine. 2004;83:360-370.
19.
Abelson R. Drug sales bring huge profits and scrutiny to cancer doctors: insurers and experts see high costs and conflicts. NY Times (Print). 2003Jan 26:A1, 18-18.
20.
Bennett CL, Bishop MR, Tallman MS, et al. The association between physician reimbursement in the US and use of hematopoietic colony stimulating factors as adjunct therapy for older patients with acute myeloid leukemia: results from the 1997 American Society of Clinical Oncology survey. Health Services Research Committee of the American Society of Clinical Oncology. Ann Oncol. 1999;10:1355-1359.
21.
Arceci RJ. Robbing Peter to pay Paul? Financial reimbursement for chemotherapy. J Pediatr Hematol Oncol. 2003;25:277-278.
22.
The Dartmouth Atlas of Health Care. Available at http://www.dartmouthatlas.org/. Accessed July 10, 2006.
23.
Gropper MA, Matthay MA. Look before you leap: how do intensivists improve care for critically ill patients. Am J Med. 2004;116:206-207.
24.
The Leapfrog Group. The Leapfrog Group for patient safety rewarding hospitals for higher performance. Available at http://www.leapfroggroup.org. Accessed July 11, 2006.
